Drugs Made In America Acquisition II Enters Convertible Note Financing

What Happened Drugs Made In America Acquisition II Corp. (the Company) filed an 8-K reporting entry into a definitive financing agreement and the issuance of convertible notes with Alpha Multi Family Office (the Investor). The Company previously issued an unsecured $150,000 bridge note on March 11, 2026. Effective March 24, 2026, the Company and the Investor signed a Definitive Investment and Sponsor Transition Agreement for a contemplated $1,400,000 convertible notes financing. On March 30, 2026, the parties executed an Interim Convertible Note (the Second Note) for $300,000.

Key Details

• $150,000 unsecured bridge note issued to Alpha Multi Family Office on March 11, 2026.
• Definitive Investment and Sponsor Transition Agreement executed effective March 24, 2026 (relates to a contemplated $1,400,000 financing).
• Interim Convertible Note of $300,000 issued March 30, 2026; matures nine months from issuance and does not bear interest.
• Upon consummation of the Company’s initial business combination, the Investor may convert outstanding principal of the $300,000 note into shares at a conversion price equal to a 35% discount to market price; proceeds intended to cover accounting, audit and other business-combination expenses.

Why It Matters This 8-K shows the Company has secured short-term financing to cover transaction-related costs as it pursues a business combination. The convertible notes create a direct financial obligation and give the investor the option to convert debt into equity at a substantial 35% discount, which could reduce the Company’s near-term cash burden but would dilute existing equity holders if conversion occurs. Retail investors should note the amounts, conversion terms and the nine-month maturity when assessing the Company’s financing position and potential dilution ahead of any business combination.